Biotech Hedge Fund Holdings & 13F Tracker

A 13F is a quarterly report that institutional investment managers overseeing at least 100 million dollars in US equities must file with the SEC. It discloses the manager's long stock positions as of the end of each quarter, including the share count and market value of each holding. Managers have 45 days after the quarter ends to file, so 13F data is a lagged but reliable window into what large funds own. The table above compiles 13F holdings for the biotech and life-sciences hedge funds we track.

Because 13F reports are filed quarterly, holdings data refreshes once per quarter, roughly 45 days after each quarter closes. We add each new quarter as funds file, and the quarter selector above lets you compare positions across earlier quarters. Between filings the holdings do not change in the public record, so quarter-over-quarter comparison is the right way to read fund activity.

Quarter-over-quarter change measures how a fund's position moved between two consecutive 13F filings. A rising position suggests the fund is building conviction, while a cut suggests rotation out of the name, though share-price moves also affect the market value of a holding. Use it to spot which funds are accumulating or exiting a given biotech stock.

We focus on the leading biotech and life-sciences specialist funds, the managers whose portfolios are concentrated in drug developers and medical innovation rather than the broad market. The tracked roster covers the largest and most active healthcare-dedicated funds, so the table reflects sector smart money rather than generalist institutions that hold a little of everything.

Biotech is a catalyst-driven, information-intensive sector, and specialist funds devote deep scientific and clinical diligence to the names they own. Tracking which stocks these funds are buying, holding, or selling gives investors a read on where informed capital is positioned ahead of data readouts and FDA decisions. Concentrated or rising institutional ownership is one signal among many, best combined with catalysts, financials, and cash runway.

A 13F shows what outside institutional managers own, reported quarterly in aggregate. Insider trades, filed on Form 4, show when a company's own officers, directors, and large holders buy or sell that company's stock, and they are reported within a couple of business days. The two are complementary: 13F reveals smart-money positioning across funds, while insider activity reveals what the people running the company are doing with their own shares.